References

Genest J, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PW, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802

Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Investigation 1993 Jul;92(1):141-146

Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Card 1998 Nov 5;82(9A):34Q-46Q.

Chu JW, Abbasi F, Kulkarni K, Lamendola C, McLaughlin T, Scalisi J, Reaven GM. Multiple Lipoprotein Abnormalities Associated with Insulin Resistance in Healthy Volunteers Identified by the Vertical Auto Profile-II Methodology. Clin Chem 2003 June 49(6):1014-1017.

Akosah KO, MD, Schaper A, Cogbill C, Schoenfeld P. Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform? J Amer Coll Card 2003 May;41(9):1475-1479.

Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996 124 S1-S9.

Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. U.S. Dept. of Health and Human Services, National Institutes of Health. NIH Publication No. 01-3670, 2001 May.

Bachorik PS, Ross JW. The NCEP Working Group on Lipoprotein Measurement: National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 1995;41:1414-20.

Marniemi J, Maki J, Maatela J, Jarvisalo J, Impivaara O. Poor applicability of the Friedewald formula in the Assessment of Serum LDL Cholesterol for Clinical Purposes. Clin Biochem 1995;28(3):285-289.

Senti M, Pedro-Botet J, Rubies-Prat J, Vidal-Barraquer F. Secondary prevention of coronary heart disease in patients with extracoronary atherosclerosis: a need for accuracy of low density lipoporotein determination. Angiology 1996 Mar;47(3):241-6.

Scharnagl H, Nauck M, Wieland H, Marz W. The Friedewald Formula Underestimates LDL Cholesterol at Low Concentrations. Clin Chem Lab Med 2001; 39(5):426–431.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502

West of Scotland Coronary Prevention Study Group. Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.

Frank M. Sacks, MD; Petar Alaupovic, PhD; Lemuel A. Moye, MD, PhD; Thomas G. Cole, PhD; Bruce Sussex, MD; Meir J. Stampfer, MD, DPH; Marc A. Pfeffer, MD, PhD; Eugene Braunwald, MD. VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial. Circulation. 2000;102:1886-1892.

Heart Protection Study Collaborative Group*. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebocontrolled trial. Lancet. 2002; 360:7-22

James A. de Lemos, MD, Michael A. Blazing, MD, Stephen D. Wiviott, MD, Eldrin F. Lewis, MD, Keith A. A. Fox, MB, ChB, Harvey D. White, DSc, Jean-Lucien Rouleau, MD, Terje R. Pedersen, MD, Laura H. Gardner, BSPH, Robin Mukherjee, PhD, Karen E. Ramsey, BS, RPh, Joanne Palmisano, MD, David W. Bilheimer, MD, Marc A. Pfeffer, MD, PhD, Robert M. Califf, MD, Eugene Braunwald, MD. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes. JAMA. 2004;292:1307-1316.

Peter S Sever, Björn Dahlöf, Neil R Poulter, Hans Wedel, Gareth Beevers, Mark Caulfield, Rory Collins, Sverre E Kjeldsen, Arni Kristinsson, Gordon T McInnes, Jesper Mehlsen, Markku Nieminen, Eoin O’Brien, Jan Östergren. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.

R. John Simes, MD; Ian C. Marschner, PhD; David Hunt, MD; David Colquhoun, MD; David Sullivan, MD; Ralph A.H. Stewart, MD; Wendy Hague, MD; Anthony Keech, MD; Peter Thompson, MD; Harvey White, MD, DSc; John Shaw, MD; Andrew Tonkin, MD; on Behalf of the LIPID Study Investigators. Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial. Circulation. 2002;105:1162-1169.

Terje R. Pedersen, MD; Anders G. Olsson, MD; Ole Færgeman, MD; John Kjekshus, MD; Hans Wedel, PhD; Kåre Berg, MD; Lars Wilhelmsen, MD; Torben Haghfelt, MD; Gudmundur Thorgeirsson, MD; Kalevi Pyo¨ra¨la¨, MD; Tatu Miettinen, MD; Bjørn Christophersen, MD; Jonathan A. Tobert, MD, PhD; Thomas A. Musliner, MD; Thomas J. Cook, MS; for The Scandinavian Simvastatin Survival Study Group. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.

Seman LJ, Deluca c, Jenner JL, Cupples LA, McNamara JR, Wilson PWF, Castelli WP, Ordovas JM, Schaefer EJ. Lipoprotein(a)-Cholesterol and Coronary Heart Disease in the Framingham Heart Study. Clin Chem 1999 45:7:1039-1046.

Crouse JR 3rd. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996 Apr;7(4):321-6.

Farnier M; Bonnefous F; Debbas N; Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994 Feb 28;154(4):441-449.

Shlipak MG et al. Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause. JAMA 2000 Apr 12;283(14):1845-1852.

Brian W. Walsh, MD; Lewis H. Kuller, MD; Robert A. Wild, MD; Sofia Paul, PhD; Mildred Farmer, MD; Jeffry B. Lawrence, MD; Aarti S. Shah, PhD; Pamela W. Anderson, MD. Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women. JAMA 1998 May 13;279(18):1445-1451.

Krauss RM. Dense low density lipoproteins and coronary artery disease. Am J Cardiol. 1995 Feb 23;75(6):53B-75B.

Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ. Role of plasma triglycerides in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994 Apr;106(2):241-53.

Brown BG, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol. 1998 Feb 26;81(4A):52B-59B.

Miller BD, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996 Nov 1;94(9):2146-53.

Vakkailanen J, et al. Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease. Circulation 2003;107:1733-37.

Watts GF, Mandalia S, Brunt JN et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas’ Atherosclerosis Regression Study (STARS). Metabolism 1993; 42:1461–1467.

Zhao XQ et al. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. Med Sci Monit 2003 Feb;9(2):CR48-

Brown BG, Zambon A, Otvos JD, Lanman RB, Morse JS, Krauss RM. LDL size or density, by four methods, as correlates of coronary stenosis change. AHA Annual Meeting abstract 2003.

Kazumi T, et al. Low density lipoprotein particle diameter in young, non-obese, normolipidemic Japanese men. Atherosclerosis 1999 Jan;142(1):113-9.

Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic market for coronary heart disease risk. Circulation 1990 Aug;82(2):495-506.

Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, Griffin BA, Williams CM. ApoE Polymorphism and Fish Oil Supplementation in Subjects With an Atherogenic Lipoprotein Phenotype. Arterioscler Thromb Vasc Biol. 2000;20:1990-1997.

Tavani A, Pelucchi, C, Negri E, Bertuzzi M, La Vecchia C. N-3 Polyunsaturated Fatty Acids, Fish, and Nonfatal Acute Myocardial Infarction. Circulation November 6, 2001:2269-2272.

Hu FB; Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women.  JAMA. 2002;287:1815-1821

Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000 Sep 5;102(10):1082-5.

Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Acstelli WP. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996 Aug 21;276(7):544-8.

von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) Further Increases the Risk of Coronary Events in Men With High Global Cardiovascular Risk. J Am Coll Card. 2001 Feb; 37(2):434–9.

Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2783-92.

Jurgens Q, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995 Oct;26(10):1841-8.

Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P, Chapman J, Passa P. Association of elevated lipoprotein (a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein (a) phenotypes. Diabetologia 1994 Jun;37(6):585-91.

Routi T, Ronnemaa T, Jokinen E, Viikari J, Niinikoski H, Leino A, Simell O. Correlation of toddlers’ serum lipoprotein(a) concentration with parental values and grandparents’ coronary heart disease: the STRIP baby study. Acta Paediatr 1996 Apr;85(4)407-12.

Cantin B, et al. Is Lp(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Card 1998 Mar 1;31(3):519.-25

Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H, Kutsunii Y, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol. 1994 Jun 1;73(15):1037-40.

Marcovina SM et al. Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a). Clin Chem 2000 46:12: 1956-1967.

Lamarche B, Moorjani S, Cantin B, Dagenis GR, Lupien PJ, Despres JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997 Jun; 17(6):1098-105.

Campos H, Roederer GO, Lussier-Cacan S, Davignon L, Krauss RM. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 1995 Aug;15(8):1043-8.

Laakso M, Pyorala K. Lipid and lipoprotein abnormalities in diabetic patients with peripheral vascular disease. Atherosclerosis 1989 Nov;74(1-2):55-63.

Moskowitz WB, Mosteller M, Schieken RM, Bossano R, Hewitt JK, Bodurtha IN, Segrest JP. Lipoprotein and oxygen transport alterations in passive smoking preadolescent children. The MCV Twin Study. Circulation 1990 Feb;81(2):586-92.

Vadlamudi S, MacLean P, Israe4l RG, Marks RH, Hickey M, Otvos J, Barakat H. Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins. Metabolism 1998 Oct;47(10):1222-6.

Brown BG et al. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. NEJM 2001 Nov 29:345(22):1583-1592.

Kulkarni KR, Marcovina SM, Krauss RM, et al. Quantification of HDL2 and HLD3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J Lipid Res, Nov 1997, 38(11): 2353-64.

Hodis HN. Triglyceride rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999;99:2852-2854.

Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994 Jan;35(1):159-68.

Kulkarni KR, Garber DW, Jones MK Segrest JP. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res, Nov 1995; 36(11): 2291-302.

Collins R. Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients. Am J Manag Care 2002 Jan;Suppl:6.

Zambon A, et al. Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression: Hepatic Lipase–Mediated Changes in LDL Density. Circulation Apr 1999; 1959-1964.

St-Pierre AC et al. Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease. Circulation 2001;104: 2295-2299.

Rosenson RS et al. Relations of Lipoprotein Subclass Levels and LDL Particle Size to Progression of Coronary Artery Disease in the PLAC-I Trial. Am J Card 2002; 90: 80-94.